Navigation Links
Dr. David L. Blecker MD, MPH, F.A.C.P. Joins Inergetics' Advisory Board to Co-Develop and Market Products to Penetrate Nephrology Market
Date:5/1/2012

PARAMUS, N.J., May 1, 2012 /PRNewswire/ -- Inergetics, Inc. (OTCBB: NRTI), announces the addition of Dr. David L. Blecker MD, MPH, F.A.C.P. to the Advisory Board.  Dr. Blecker, a graduate of Tufts University School of Medicine, has been practicing medicine for over 39 years and is currently the Chief in Nephrology at AtlantiCare Regional Medical Center.  Dr. Blecker is also the Founder of Regional Nephrology Associates, a private practice located in south New Jersey.  In addition, Dr. Blecker is an owner and operator of five Dialysis units as well as partner in Regional Nephrology Associates.  He has performed clinical trials for various pharmaceutical companies including Amgen Inc., Pfizer  and Merck. 

"As an expert in preventive medicine and an advocate for clinical trials, I believe that the proprietary technology of Surgex allows athletes, as well as our soldiers, to function at a high performance level without the loss of muscle mass." Dr. Blecker further stated, "A technology that limits muscle waste can be utilized within the medical sector with a focus on degenerative diseases such as cancer and kidney disease."  

Dr. Blecker stated, "As an advisory board member of Inergetics, I plan on developing a product and marketing strategy to reduce protein deficiency that exists within dialysis patients." 

CEO Mark Mirken commented, "Dr. Blecker's access and experience with dialysis patients is extensive and will allow him to conduct clinical trials within his numerous dialysis units.  This product is based on our existing long term care and immune compromised technology and will be accretive to our product portfolio targeting nutritional supplements for the medical marketplace."

About Inergetics, Inc. 

Inergetics, Inc. is a leading developer of nutritional supplements for the Clinical Health and Sports Supplement markets. Inergetics has developed the Surgex® sports nutrition formula to meet the nutritional needs of professional, Olympic and amateur elite athletes that experience post-workout symptoms such as fatigue, loss of lean muscle, oxidative stress, and reduced immune function.  Additionally, Inergetics has established a line of Resurgex™ products that provide comprehensive nutritional support for actively treated cancer patients as well as those in post-treatment care and elderly members of the assisted living community.  To learn more about Inergetics, visit www.inergetics.com, the Resurgex™ product website and online store, and www.resurgex.com, and the Surgex® product website and online store at www.surgexsports.com.

Safe Harbor Statement   

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical fact, including, without limitation, those with respect to the objectives, plans and strategies of Inergetics set forth herein and those preceded by or that include the words "believes," "expects," "given," "targets," "intends," "anticipates," "plans," "projects," "forecasts," or similar expressions, are "forward-looking statements." Although Inergetics' management believes that such forward-looking statements are reasonable, it cannot guarantee that such expectations are, or will be, correct. These forward-looking statements involve a number of risks and uncertainties, which could cause Inergetics' future results to differ materially from those anticipated. Inergetics assumes no obligation to update any of the information contained or referenced in this press release.

Investor Contact

John Zervas
(888) 437-4804


'/>"/>
SOURCE Inergetics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Omeros Appoints David A. Mann to its Board of Directors
2. [video] David Brown, President and CEO of LifeVantage Corporation, Discusses Record Page Views on WallSt.nets 3-Minute Press Show
3. Encorium Appoints David Ginsberg President and Chief Executive Officer, Announces Changes to the Board of Directors
4. Trusted LASIK Surgeons Welcomes Leading LASIK Eye Surgery Expert, Inventor David Huang, M.D., Los Angeles, to Its Unique Lasik Directory Service
5. David Hsia, Ph.D. Joins Kinex Pharmaceuticals Board of Directors
6. Lumiphore Partners with Biophor Diagnostics, Inc. to Develop Tests for Drugs of Abuse; Appoints Ibis Biosciences Founder David J. Ecker to Board
7. Pacira Pharmaceuticals, Inc. Adds Experienced Physician Dr. David St. Peter to Leadership Team
8. David H. Murdock Research Institute Taps Waters for Laboratory Technology
9. PercSys Names David Auth and Howard Palefsky to Its Board of Directors
10. Prominent Urologist Dr. David B. Samadi Presents Breakthrough Robotic Surgery Techniques on OR Live Webcast
11. BrainCells Inc. Appoints David E. Thompson to Its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , Feb. 23, 2017 /PRNewswire/ - The Fight ... for Cancer Research (OICR) are pleased to report that ... A financing, with Johnson & Johnson Innovation – JJDC, ... include venture groups HealthCap, TPG Biotechnology Partners, and Genesys ... ...
(Date:2/23/2017)... Atlanta, it seems everyone has a chance to express their ... expressive and dynamic community unlike any other. The businesses that ... With their newest salon in ... on that tradition with a unique, fresh approach to head ... the newest of 13 nationwide locations, each of them well-situated ...
(Date:2/23/2017)... 2017  Imanis Life Sciences announced today the ... vaccinia viruses for virotherapy research. These viruses are ... proprietary, vaccinia virus-based technology platform for research use. ... a partnership with Genelux to offer researchers, for ... use in research," said Dr. Kah Whye ...
(Date:2/23/2017)... (PRWEB) , ... February 23, ... ... Inc., announced today that in a published evaluation of multiple immunoassay-based threat ... U.S. Department of Energy Laboratory, PathSensors’ CANARY® biosensor threat detection technology was ...
Breaking Biology Technology:
(Date:1/31/2017)... CAMBRIDGE, Mass. , Jan. 31, 2017 /PRNewswire-USNewswire/ ... develop novel therapies for the treatment of bacterial ... generation set of antibacterial candidates from Pro Bono ... the increased prevalence of multi-drug resistant forms of ... by Cantab Anti Infectives Ltd, a PBB group ...
(Date:1/26/2017)... , Jan. 26, 2017  Acuity Market Intelligence ... Biometrics and Digital Identity".  Acuity characterizes 2017 as ... when increased adoption reflects a new understanding of ... "Biometrics and digital identity are often perceived ... Maxine Most , Principal of Acuity Market intelligence. ...
(Date:1/24/2017)... , Jan. 24, 2017  It sounds ... baby,s sock that monitors vital signs and alerts ... an infant,s oxygen saturation level drops. But pediatric ... alarm to parents, with no evidence of medical ... devices are marketed aggressively to parents of healthy ...
Breaking Biology News(10 mins):